

THE BLOOD SERVICE'S YEAR

# 2021



**LINK IN  
A CHAIN OF  
HELPERS**

Finnish Red Cross   
Blood Service



More information:  
vuosikertomus.  
veripalvelu.fi/en

# THE BLOOD SERVICE IN A NUTSHELL

## THE BLOOD SERVICE IN THE FINNISH HEALTHCARE SYSTEM

■ The Blood Service is part of the Finnish Red Cross and serves Finnish healthcare. We are responsible for supplying blood products all over Finland in a centralised manner. Our tasks include organising blood donations and collecting blood as well as testing donated blood, manufacturing blood products and distributing them to hospitals.

We provide healthcare sector services such as blood cross-matching and tests needed for organ, tissue and stem cell transplants. The Blood Service performs blood group and blood group antibody tests for all pregnant women. The Blood Service also hosts the Finnish Stem Cell Registry, which provides stem cell grafts for patients.

Our strong expertise is built on in-house research and development, which forms the foundation for safe blood transfusions and novel cell therapies now and in the future.

We help others to save lives. We operate together with voluntary donors and hospital professionals. •

### CONTENTS:

- The Blood Service in a nutshell ..... 2
- Review by the Chief Executive ..... 4
- Operational reviews ..... 5
- Finances and social responsibility..... 13
- Staff ..... 15

Veripalvelu® is registered trademark



**PRODUCTION AND LAYOUT:**  
Mediafocus Oy  
**TEXTS:**  
FRCBS Communications  
**PHOTOS:** FRCBS  
**PRINTING HOUSE:**  
Grano Oy, 2022



## Helping patients is a joint effort

We work to help patients get better. Together with blood donors, the Blood Service supports hospitals in treating patients. A host of volunteers assists us in organising blood donation events.

## We are expert professionals

The Blood Service operates in nine towns and cities and employs about 500 professionals, all experts in their field. We provide blood and cell products and associated laboratory and expert services for the healthcare system.

## We are a non-profit organisation

The Blood Service is an independent, non-profit unit of the Finnish Red Cross. We cover the costs of our operations and their development by selling cell and blood products and expert services to the Finnish healthcare system. We are responsible for maintaining good operational efficiency and overall economic efficiency.



## REVIEW BY THE CHIEF EXECUTIVE

**T**he coronavirus pandemic remained with us throughout the year, simply moving from one stage to the next. The safety precautions and processes rapidly implemented in 2020 required continuous, precise management, expert work and the ability to react. Remote working shaped our working community, and because of the safety measures the necessary in-house work was highly demanding in many respects. Donors adapted to the changes well. By working together, we managed to keep our operational capacity stable and manageable with no disruptions to our hospital services.

The pandemic highlighted the importance of having a stable financial situation for our ability to act. Our main source of income, blood product sales, did not increase even though costs did. Our firm financial footing enabled us to continuously develop our digital services and ability to react. The electronic health survey for blood donors introduced in 2020 proved to be highly valuable in 2021, as more donor candidates could become donors. The percentage of non-donors, particularly of those registered as new donors, halved in less than two years, which saved both donors' time and effort and work carried out by the Blood Service.

To ensure continuity, it was important that we were able to keep our research and development operations active and receive the necessary external funding. At the same time, the first research grants were awarded from the Blood Service's research fund to exter-

nal projects that deal with the Blood Service's strategic research topics but which cannot be conducted by the Blood Service itself. Active national and international research and development collaboration is a critical success factor, and 2021 was a very productive year in this respect.

Our strategy period ended in 2021, so at the end of the year we started looking to the future. In autumn 2022 we will move to new premises in Vantaa, and this will support our strategic renewal. Manufacture, laboratories, storage and many other operations will benefit from the new technology, enabling us to respond even better to the ever-changing needs in the treatment of patients. Our new premises will support the stability, continuity and efficiency of our mission.

I'd like to express my warmest thanks to all blood and stem cell donors for their commitment and sense of responsibility in safeguarding the treatment of patients. Every day someone's life depends on the gift given by

donors and we cannot wait for a steadier situation. Despite the tough circumstances, the personnel at the Blood Service have invested their entire know-how in distributing the gift of life for those in need. Thank you for keeping the chain of help intact.

**Pia Westman**  
Chief Executive of the Blood Service

**Thank you  
for keeping  
the chain  
of help  
intact.**



# OPERATIONAL REVIEWS



## BLOOD DONATION

■ During the second year of the coronavirus pandemic, the monthly fluctuation in the sales of red blood cells and thus the number of blood donors was smaller than 2020. The booking system for blood donation helped to coordinate blood donation activities and was very popular among donors. Due to the coronavirus pandemic, we had to rapidly introduce safety precautions in our customer premises as well as change our usual practices.

Blood was collected in line with the needs of hospitals throughout the year. 113,006 persons registered for blood donation 198,193 times. Whole blood was collected 185,326 times, about 2% less than in 2020. More than half of whole blood donations took place at our 10 Blood Service units. We also organised 1,115 mobile blood donations events. >>


### Blood group distribution among donors in Finland

New blood donors in 2021

A+	A-	B+	B-	AB+	AB-	O+	O-
35%	5%	15%	2%	6%	1%	30%	5%


Blood donors are invited to donate on the basis of their blood group.

### Whole blood donations



Blood is collected in line with the needs of hospitals.


### Number of donations per person in 2021



Finnish blood donors donate blood 1.66 times per year on average.



### Blood donors' age and gender distribution in 2021




The group with the most blood donors is young women.

### Percentage of non-donors out of those registered (%)

	2019	2020	2021
New donors	25.9%	17.6%	13.1%
Previous donors	8.3%	6.2%	4.6%
Women	11.5%	8.8%	6.5%
Men	7.6%	5.4%	4.0%
Total – all of Finland	9.7%	7.3%	5.3%

A considerably bigger proportion of donor candidates are being accepted as donors. The main reason for this positive change is the introduction of an electronic health survey that is completed beforehand and gives instructions to donors.



» A total of 2,310 machine-aided platelet collections were carried out. These collections, about 4,400 products in total, covered 13% of all platelet products supplied. Machine-aided platelet collections are usually patient-specific and urgent.

New blood donors are needed all the time. Nearly 16,000 new donors were recruited during the year, 14% of all donors. Recruitment was carried out through channels such as social media and by working together with sports clubs, educational institutions, the Finnish Red Cross and the Finnish Defence Forces. Due to the coronavirus pandemic, fewer blood donation events than usual were organised with our partners.

Over 34,000 of the visits were thanks to active voluntary donor group members, "BloodGroup" members, which was about 30% more than in 2020. There were 3,862 active BloodGroups in 2021, and 664 new BloodGroups were set up.

Satisfaction among donors remained high despite the changing circumstances. 96% of more than 40,000 donors who gave customer feedback were highly satisfied. The NPS score regarding recommending blood donations was 94.7, which was excellent too. •



## BLOOD PRODUCTS

■ The manufacture of blood products involves separating donated whole blood into red blood cells, platelets and plasma. We distribute these blood products to all Finnish hospitals in line with the needs of medical care.

It was feared that the coronavirus pandemic would pose major challenges to hospitals and at the Blood Service. However, with careful monitoring and management, activities remained steady.

179,906 red blood cell products were sold to clients for patient treatment, 0.3% more than in 2020. The need for the other main product, platelets (thrombocytes), increased in hospitals by 0.9%. Sales of medicinal frozen plasma (octoplasLG) to hospitals by the Blood Service increased by 2.0%.

Product stocks remained manageable throughout the year, and the donated blood was utilized efficiently in manufacture. A unique feature of the need for blood products in 2021 was the exceptionally high number of patient-specific HLA-typed thrombocytes required, which was due to an increased need in the treatment of blood cancers.

### Blood product sales to hospitals

Product, units	2019	2020	2021	change % 2020-2021
Red blood cells (without white blood cells)	190,437	179,387	179,906	0.3%
Platelet products (including apheresis products)	31,621	31,381	31,676	0.9%

Development work focused on planning our new manufacturing premises. Once they are completed in Vehkala, Vantaa, in 2022, we will be able to make improvements in areas such as working conditions in our manufacturing premises, product storage and logistics. We have already renewed all materials used in transporting donated blood and blood products. •

### Use of donated whole blood for preparation of blood products

	Red blood cells	Platelets**
Products used in blood transfusions	97%	87%
Removals related to blood donation	1%	-
Removals related to laboratory results and the manufacturing process	1%	2%
Others not used for blood transfusions (expired or supplied for medicines manufacture)	1%*	11%

\* Some red blood cells not used for blood transfusions are sent for use as raw material for a medicinal product used for the treatment of porphyria  
 \*\* Proportions of platelet products; manufactured using only some of the donated whole blood units

In Finland, the use of blood for the treatment of patients is highly efficient. Red blood cell products can be used for about five weeks and platelets for about five days after donation.





### Blood Service laboratory tests for healthcare units

	2019	2020	2021
Tests for blood typing	12,623	13,180	14,551
Red blood cell antibody identification	3,990	4,086	4,712
Blood compatibility tests performed urgently and during on-call times	2,314	2,327	2,668
Tests on maternity clinic specimens	69,115	73,063	72,087
Tissue compatibility tests	10,656	10,107	10,493

### HIV and hepatitis (B and C) viruses and syphilis in blood donor samples

	2017	2018	2019	2020	2021
Hepatitis B	3	2	5	6	9
Hepatitis C	4	4	8	8	8
HIV	1	2	1	1	1
Syphilis	6	4	9	7	12

Careful donor selection ensures that very few carriers of the HIV or hepatitis viruses are identified when the blood is tested for infection.

### Organ transplantations performed in Finland

(Source: ScandiTransplant)

	2017	2018	2019	2020	2021
Kidney	240	238	293	263	268
Liver	63	66	64	75	75
Heart	26	47	30	22	22
Lungs	24	18	27	21	24
Pancreas	21	23	39	26	31
Small intestine	0	0	0	1	0
<b>TOTAL</b>	<b>374</b>	<b>392</b>	<b>453</b>	<b>408</b>	<b>420</b>
From deceased Finnish organ donors	116	108	141	121	119
From live Finnish organ donors (kidney)	29	32	25	31	46

The Blood Service performs tissue typing for all organ transplantations performed in Finland and assesses tissue compatibility between the transplant recipients and the organ donors in a centralized manner.

## LABORATORY SERVICES


■ Our Laboratory Services conduct tests to ensure the safety and quality of the Blood Service's blood and cell products and to meet various healthcare needs.

The effects of the coronavirus pandemic on our laboratory services were relatively minor. Problems occurred mainly in sample logistics and in coordinating sample deliveries during on-call times. To support hospitals during the pandemic, we added to our test selection a consultation on red blood cell antibody testing.

As regards the laboratory testing performed for healthcare clients, the number of blood typing tests increased, which was also reflected in the number of tests during office hours. The numbers of tests on maternity clinic specimens and tissue compatibility tests were similar to previous years.

In the development of operations, the focus was on making preparations for the new premises and for the technology update in 2022. The new premises in Vehkala, Vantaa, will have a new automated line to be used in the processing of blood donor and maternity clinic specimens as well as in the infection screening required to ensure the safety of blood products. Blood group analysers and the analytical processes used in testing maternity clinic specimens and patient samples will also be updated. •





## STEM CELL REGISTRY

■ The Finnish Stem Cell Registry, which is run by the Blood Service, belongs to the global network of registries providing stem cell grafts. We recruit voluntary donors to the Registry in a targeted manner. Our Registry closely supports the Finnish and Estonian stem cell transplant centres. We search for compatible donors for patients in need of a stem cell transplantation in registers in Finland and other countries. We also organise graft collections from Finnish donors and deliver the grafts collected by national and foreign registries to transplant centres.

Over the year, 6,381 new members joined the Stem Cell Registry, twice as many as in 2020, bringing the number at the end of the year to over 62,000. We supplied 138 grafts to stem cell transplant centres treating patients. Our couriers helped delivering 110 stem cell grafts to and from other countries in line with the special arrangements required by the coronavirus pandemic. To ensure smooth and secure operations, particular attention was given to improving the Stem Cell Registry's IT systems. •

## Grafts delivered by the Stem Cell Registry

### Grafts supplied, total

	2019	2020	2021
Bone marrow graft	11	24	23
Blood stem cell graft	105	117	107
Cord blood graft	1	3	1
Lymphocyte graft	9	9	17
Total	126	153	138

There are various ways to collect stem cells from donors. Harvesting the cells from the donor's bloodstream is by far the most common method. Besides Finland, the Stem Cell Registry delivers transplants to Estonia.

### From a Finnish donor to a Finnish patient

	2019	2020	2021
Bone marrow graft	0	5	4
Blood stem cell graft	21	15	25
Cord blood graft	1	0	0
Lymphocyte graft	0	0	4
Total	22	20	33

### From a non-Finnish donor to a Finnish patient

	2019	2020	2021
Bone marrow graft	8	15	15
Blood stem cell graft	58	63	52
Cord blood graft	1	0	0
Lymphocyte graft	8	6	11
Total	75	84	78

### From a Finnish donor to a non-Finnish patient

	2019	2020	2021
Bone marrow graft	3	2	3
Blood stem cell graft	12	22	13
Cord blood graft	0	3	1
Lymphocyte graft	0	3	2
Total	15	30	19

The Stem Cell Registry operates internationally. The Blood Service's couriers bring in stem cell grafts from abroad and deliver grafts collected from Finnish donors to foreign patients.



## CELL PRODUCTION CENTRE

■ Our Cell Production Centre researches, develops and manufactures new cell therapy products for use in healthcare. Between 2013 and 2021, a total of 117 patients received experimental cell therapy products and tissue products manufactured by the Blood Service.

We provided products such as mesenchymal stromal cell products (LY-MSK) for the treatment of immunological problems due to blood stem cell grafts as well modified haploidentical stem cell grafts for the treatment of paediatric patients.

At the Cell Production Centre, we are currently conducting several projects to develop cell therapy products for the treatment of refractory cancers. For this purpose, we are developing CAR T-cell products and NK cell products. Our operating conditions will significantly improve in 2022, once the modern cleanrooms for the manufacture of cell therapy products are completed in our new premises in Vehkala, Vantaa. •

## MEDICAL SERVICES AND CONTACTS WITH CLIENT HOSPITALS

■ Our physicians participate in patient care by giving opinions and answering questions about the patient samples tested in the Blood Service laboratory. They also support hospitals during on-call times via telephone consultations on issues such as blood transfusions. Our contact network consists of healthcare professionals involved in



blood transfusion treatments from all university and central hospitals.

We regularly measure our hospital clients' satisfaction by means of surveys. In the survey carried out in 2021, blood product clients gave the Blood Service an excellent overall score of 9.4 on a scale of 4 to 10. The pandemic and the logistical challenges it caused did not affect clients' satisfaction, which was as good as in previous years.

Meetings with blood unit clients are an important aspect of managing the blood supply chain and transmission of information. We also organised many training events for healthcare professionals. All communications and meetings were conducted remotely.

Together with clinical experts in hospitals, we are improving the safety and effectiveness of blood transfusions as well as the optimal use of blood products. A new area for development is the use of whole blood products in emergency medical treatment and creating the readiness to produce them. •



## RESEARCH

■ The Blood Service’s scientific research is guided by the focus areas specified in the research strategy:

- Blood supply chain
- New cell therapies and compatibility of organ and tissue transplantations

In 2021, we spent nearly 4 million euros on research, 2.4 million of which (62%) was covered by external funding. In past years, our research budget has been 3 to 4 million euros, over half of which has been covered by external funding.

Our key researcher resources comprise 19 persons each with a doctoral degree. Researchers at the Blood Service contributed to 22 peer-reviewed scientific publications in 2021.

Over 50,000 blood donors have already joined the Blood Service’s Biobank and given their consent for their blood samples to be used in research projects. We have created a set of screening tools that can be used with the Biobank’s genomic data to improve blood product compatibility in terms of HLA factors or blood groups.

We develop cell therapy products for clinical research based on collaboration agreements. The iCell research group was founded to produce scientific data to support cell manufacture. The group has received a significant amount of external funding.

We are also piloting a new product for research use that involves vesicles produced by blood cells.

**Numbers of peer-reviewed scientific publications at the Blood Service by research area**

Research area	Total	2017	2018	2019	2020	2021
Blood supply chain	23	3	4	4	5	7
Blood cells	8	2	1	3	1	1
Cell therapies	15	3	4	6	2	0
Transplantations	33	8	7	6	5	7
Other areas	29	9	3	4	6	7
<b>Total</b>	<b>108</b>	<b>25</b>	<b>19</b>	<b>23</b>	<b>19</b>	<b>22</b>

Our researchers also use extensive data sets to create prediction models. We can now predict issues such as obstacles to blood donation due to low haemoglobin as well as the trend in the use of blood products. Together with transplant centres, we are also looking for new tools with which to assess and predict complications in organ and stem cell transplantations.

The first research grants, 495,000 euros in total, were awarded from the Blood Service’s research fund to nine research projects outside the Blood Service. The projects deal with cell therapy, blood cells and kidney transplantations. Research grants can be awarded to those research projects outside the Blood Service that promote the objectives of the Blood Service’s research strategy. •



## OTHER OPERATIONS

■ **Quality management** ensures the Blood Service's operations meet the requirements of the legislation, authorities, accreditation bodies and pharmaceutical industry stakeholders.

In the further development of quality management, emphasis was placed on addressing digital development needs: data protection, reliability of digital tools and the development of an electronic quality management system. We also produced new modelling for our workflow processes and prepared for the move to the new premises in 2022.

The number of audits we performed has doubled since 2020. There were 20 internal audits and almost as many external audits and distributor surveys. Our tissue establishment operations received a new accreditation from the World Marrow Donor Association.

In **Digital Services**, we continued the digital development of the blood supply chain. Our intention is to supplement the core applications in the enterprise resource planning system for the blood supply chain, and to produce new electronic services for donors and hospital clients.

We introduced our new electronic ordering system for the first clients. Using this system, clients can order the products they need and view the order progress, order history and the stock situation at the Blood Service's different distribution units. This system will be available to all clients within a few years. We also updated the appointment booking service for blood donors.

In **Communications and Marketing**, we emphasized the importance of continuity of blood

donations and their safety despite the exceptional circumstances. Fairs, events and other face-to-face communications were halted due to the pandemic, so donors were activated more than before, via social media and personal invitations. Advertising and communications were produced every day throughout the year, the focus being on digital channels.

The Blood Service partnered up with Facebook, giving us access to Facebook's blood donation tool which helped us to activate donors. We produced content for several publications and channels. New male members were recruited for the Stem Cell Registry. Of those registered during the campaign, more than 70% were men.


We published a section on blood donation in the study material portal by the Red Cross. We also updated our intranet to strengthen internal communications.

Construction of our new headquarters is being coordinated by our **Technical Services**. The premises in Vantaa will meet our requirements well into the future. The project progressed as scheduled in 2021, and we will move to the new premises in autumn 2022. •






# FINANCES AND SOCIAL RESPONSIBILITY



Turnover by product group (million euros)

	2020	2021	Change	Percentage of turnover
Blood products	36.6	36.8	0.2	64.4%
Laboratory tests	6.1	6.3	0.2	11.0%
Plasma material	6.5	6.2	-0.3	10.9%
Cell and tissue therapy services	4.6	4.2	-0.3	7.4%
Medicines	2.9	3.0	0.1	5.3%
Other	0.5	0.6	0.1	1.0%
<b>Total</b>	<b>57.2</b>	<b>57.2</b>		


Blood products account for most of the Blood Service's turnover.



Cost distribution, 2021 (%)

Personnel costs	46%
Materials and subcontracting	26%
ICT	8%
Rents (premises and equipment)	6%
Facility and equipment maintenance	5%
Investment expenses	4%
Logistics	3%
Other	2%

Personnel costs are the Blood Service's biggest single cost item.



Cost breakdown for one bag of blood, 2021 (%)

Blood donation activities	56%
Laboratory activities	26%
Production	11%
Storage and transportation	5%
Medical support	2%

The cost of a blood product consists of several factors.

The Blood Service is a non-profit organisation. Its activities are financed by the sales of products and services to health-care organisations. The Blood Service is not supported by government funds or other external sources, except for grants and subsidies for research projects. Any financial surplus is not shared but instead used to ensure the continuation and development of activities.

Turnover was €57.2 million, as on the previous year. Our operating result showed a deficit, but the strong rise in the securities market turned the internal result profitable. Net profit for the financial year was €5.9 million. Financial income accounted for €7.5 million of the financial result.

Personnel costs increased by 3.2%. Material and subcontracting expenses were up by 2.3%. Other costs, the largest of which were incurred by premises, ICT and logistics services, increased by 0.1%.

At the end of the financial period, the Blood Service's internal balance sheet shows total capital of >>

# Social responsibility indicators

	2019	2020	2021
<b>ECONOMIC INDICATORS</b>			
Turnover, €1,000	58,792	57,237	57,162
Materials and services, €1,000	-14,967	-14,686	-14,866
Personnel expenses, €1,000	-24,194	-24,604	-25,263
<b>SOCIAL INDICATORS</b>			
Number of personnel, full-time (FTE), average	428	425	423
Days lost through sickness	4,805	4,630	4,240
Accidents at work	25	38	32
Personnel training, €1,000	-247	-110	-162
Personnel training, €/person	558	248	365
Personnel satisfaction ***	81%	4.2	4.1
Personnel satisfaction, Employee Net Promoter Score (eNPS)	50	54	54
Satisfaction among blood donors, Net Promoter Score (NPS)	92	93	95
Client satisfaction (on a scale from 4 to 10)	9.4 n=74	9.4 n=278	9.4 n=104
<b>ENVIRONMENTAL INDICATORS</b>			
Electricity consumption, MWh *	6,043	5,781	6,032
Water consumption, m <sup>3</sup> *	11,268	11,046	12,423
District heat consumption, MWh *	4,303	3,682	4,827
Incinerable waste, kg *	52,720	49,476	62,397
Sorted municipal waste, kg **	174,693	168,426	156,095
Hazardous waste, kg *	6,844	3,429	9,541
Travel days	11,508	10,540	10,540
<b>OTHER INDICATORS</b>			
Number of blood donations (whole blood and platelets)	200,822	190,601	187,548
Number of blood donors (whole blood and platelets)	114,353	111,104	109,989
Persons registered at blood donations	124,843	118,452	113,006
Reported adverse reactions of blood transfusion	342	327	283
Grafts delivered by the Stem Cell Registry	126	153	138
Number of members in the Stem Cell Registry (31 December)	52,176	55,100	62,577

\* Kivihaka, Helsinki, including municipal waste and energy consumption by the subtenants, which have increased.

\*\* Incinerable special biomedical waste also includes waste from Helsinki mobile blood collection unit.


\*\*\* Personnel satisfaction was measured using the "2018-2019 Trust Index®", the maximum overall score of which is 100%. In 2020, the "Työvire" staff survey was introduced; the results vary from 1 to 5. The score for 2021 was excellent.

» €94.4 million. €23.1 million of this is in an independent fund of the Finnish Red Cross, the purpose of which is to support research and development activities at the Blood Service. €55.4 million was invested in securities, and the bank balance was €30.3 million. A solid balance sheet will secure the continuity of the Blood Service's critical functions for months with no disruptions despite the exceptional circumstances.

The Blood Service prepares an internal profit and loss account and balance sheet on its operations. The Blood Service's financial result is included in that of the Finnish Red Cross, on which no auditor's report had been issued at the date of signing the Blood Service's balance sheet book.

The use of blood products in Finland has declined by some 26% in 10 years.

The Blood Service has adjusted well to the situation, and there has been no need to increase the prices of blood products since 2014. After two years with the coronavirus pandemic, it will be interesting to see where the need for blood products in health care will settle and how soon. •



## STAFF

In 2021, the Blood Service had an average of 510 employees, whose contributions total the equivalent of 423 full-time employees (FTEs). The mean age of our employees was 43 years. Of our personnel, 87% were female and 13% male.

During the second year of the coronavirus pandemic, the health of our staff remained good. Most of the work at the Blood Service, such as blood donations, manufacture and laboratory work, requires being constantly at the workplace. Our staff adhered to the safety precautions extremely well, and no major quarantine measures were necessary. Remote working was common. The measures of well-being at work continued to be relatively good, as in previous years. Sickness leave was 3.3% of theoretical working hours, and there were 32 work-related injuries.

A staff survey showed that work tone within the organisation and the willingness to recommend the Blood Service as an employer got an excellent score again. We also take good care of our young summer employees. We again took part in the Responsible Summer Job campaign, where 9,458 summer employees responded from 129 organisations. Our ranking among big companies was 6. •

### Number of personnel, average

	2020	2021
Total number of personnel, average	502	510
Number of personnel, full-time (FTE)	423	423
Full-time employment	444	443
Permanent	393	392
Temporary	109	118
Full-time	377	377
Part-time	103	105
On-call	22	29
Long absences	37	39

### Distribution of personnel in the organisation (%)

	2021
Blood donation	40%
Products and Medical Services	33%
Quality Management, Research and Product Development	14%
Support services	13%

### Education demographics (%)

NURSING Nurse, specialist nurse, public health nurse	40%
LABORATORY Clinical laboratory technologist, laboratory technician, laboratory analyst, medical laboratory technologist, special laboratory technician	16%
NATURAL SCIENCES B.Sc., M.Sc., Ph.Lic., Ph.D.	8%
SOCIAL SERVICES AND OTHER HEALTHCARE Practical nurse, auxiliary nurse	8%
BUSINESS QBA, BBA, BSc (Econ)	6%
PHARMACY B.Sc. (Pharm), M.Sc. (Pharm), Pharmaceutical Assistant	6%
MEDICINE Lic.Med., D.Med.Sc., Specialist	3%
TECHNOLOGY M.Sc. (Technology), technician, other education in the field of technology	3%
Other education	10%

The education demographics are from 2020. Annual changes are minor, and education data are not compiled annually.

Finnish Red Cross  
Blood Service



## DONOR CENTRES

**BLOOD SERVICE CENTRE  
HELSINKI, KIVIHAKA**  
Kivihaantie 7, 00310 Helsinki  
tel +358 29 300 1010

Donor information, free of charge  
tel +358 800 0 5801  
(weekdays, 8am–5pm)

**ESPOO**  
Iso Omena Shopping Centre  
Service Centre  
Suomenlahdentie 1, 02230 Espoo

**HELSINKI, SANOMA BUILDING**  
Töölönlahdenkatu 2, 00100 Helsinki

**JYVÄSKYLÄ**  
Kolmikulma, Puistokatu 2–4  
40100 Jyväskylä

**KUOPIO**  
Puijonkatu 23, 70100 Kuopio

**LAHTI**  
Trio Shopping Centre  
Hansakuja Kauppakatu 10, 15140 Lahti

**OULU**  
Isokatu 32 C, 90100 Oulu

**SEINÄJOKI**  
Kauppakatu 26, 60100 Seinäjoki

**TAMPERE**  
Koskikeskus Shopping Centre  
Hatanpään valtatie 1, 33100 Tampere

**TURKU**  
Yliopistonkatu 29 b (3rd floor)  
20100 Turku

The Blood Service also organises blood donation events every weekday in different places in Finland. More information on timings and venues on our website.

**[WWW.BLOODSERVICE.FI](http://WWW.BLOODSERVICE.FI)**